Biosimilar monoclonal antibodies: a science-based regulatory challenge.
about
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal AntibodiesClinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimodSeparation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applicationsBiosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab.Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.Future directions in inflammatory bowel disease management.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Differentiating biosimilarity and comparability in biotherapeutics.Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.The road from development to approval: evaluating the body of evidence to confirm biosimilarity.Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
P2860
Q26738325-25B7DB60-F8E4-4785-8E17-BB59DB1B7B96Q26740235-1BA66634-D702-4068-9530-72686150A0A7Q26824543-4E7B6690-8DDF-4B60-9259-AA744271A8E0Q30393052-105A043E-CA52-4F9E-8CC9-7330817EB43AQ33881234-3598B278-FED0-4295-B5E3-9C9A5B99B596Q34486159-6AB93045-DFE0-4A3A-ABD0-1B19BA969068Q37305536-22BE3399-7EEE-4852-ACE6-8CC22C0460AAQ37703405-071F29BC-FA9C-4B9A-9E3F-EE843CE9697DQ38205305-1C741E7A-4DFD-447C-8A53-0348EBB8D7B4Q38394272-68B5F152-3247-4E34-826B-DB610BC7D19DQ38591241-886CC28A-8BC6-49EF-BFF8-F5AE5AB28A96Q38979267-F5EEF5CD-1EA6-47C5-B951-E5BC5C1A2A7FQ39080325-C4266D43-D328-422B-BB6A-2D2A61E34822Q47950956-0C760D52-59BD-4C56-92EB-E9B7FDA9A24DQ50696748-EA2802B5-853E-4B0A-9FF1-E21537FE146A
P2860
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
@en
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
@nl
type
label
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
@en
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
@nl
prefLabel
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
@en
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
@nl
P2860
P1476
Biosimilar monoclonal antibodies: a science-based regulatory challenge.
@en
P2860
P304
P356
10.1517/14712598.2012.758710
P407
P577
2013-01-04T00:00:00Z